SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention over the wait for the 80th overall-survival event in its Phase 3 REGAL AML trial and the companys quiet period; the last reported count was 78, and no new result is confirmed. Bulls view the prolonged wait as a possible sign of extended survival on GPS, while bears question the trial and disclosure timeline, and the selloff has fueled debate over whether market and options pressure or company-specific concerns are driving the move.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has turned the discussion from Black Monday crash warnings to whether the market can sustain the bounce. Traders debate whether it reflects genuine dip-buying or a fragile overnight short-covering move, with some linking optimism to possible Russia-Ukraine developments and easing oil prices while others expect a reversal.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has put QQQ under pressure, while a strong rebound in futures prompted traders to debate whether the bounce can hold or is a bull trap. Black Monday anniversary crash warnings amplified the volatility, but many traders dismissed them as the rebound gathered momentum.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor-sector selloff and volatile rebound, with traders debating whether the bounce marks a bottom or is a temporary rally. The bearish case centers on worries about AI spending, debt, inflation and Chinese competition, while dip buyers point to continued chip demand and the sectors oversold condition.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is caught in a broad semiconductor selloff as investors question whether AI infrastructure spending can justify high valuations, with inflation and interest-rate concerns adding pressure. Traders are split between expecting further downside and treating the decline as a buying opportunity, while some point to Intels foundry prospects and upcoming earnings as reasons for optimism.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on lifileucel is driving attention: traders are weighing mature frontline melanoma results and early sarcoma responses as encouraging signs, while noting the small cohorts and need for confirmation in larger trials. The sharp pullback is widely viewed in the discussion as part of broader biotech and market weakness rather than a clear company-specific reaction.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep decline is drawing attention to staged IPO lockup expirations, which make more shares eligible for sale, alongside weakness across AI and semiconductor stocks. Traders are split between viewing the selloff as a buying opportunity and worrying that potential insider selling, high valuation and customer-concentration concerns could prolong pressure.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as investors question the sectors debt-fueled expansion, financing costs, and path to returns. Traders are split between viewing the decline as an overdone pullbackoften arguing Nebius is better positioned than some peersand expecting further downside amid sector-wide risk concerns.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCIs steep selloff is drawing attention amid a broader pullback in AI and semiconductor stocks, with traders also focused on renewed governance and export-control concerns after a contractor pleaded guilty in a server-smuggling case. The debate centers on whether the decline is an overdone sector-driven drop or reflects company-specific risks ahead of earnings; bulls cite valuation and AI demand, while bears question management credibility and the outlook.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on TG Therapeutics MSToronto clinical presentations, especially initial Phase 1 azer-cel results in progressive MS, alongside BRIUMVI long-term and dosing data. Traders are anticipating a catalyst for the shares, though some are frustrated by the recent range-bound trading and buyout talk remains speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gentex (GNTX) Reports Next Week: Wall Street Expects Earnings Growth

Gentex (GNTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Visteon (VC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Visteon (VC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Visteon Declares Quarterly Dividend of $0.375 Per Share

Visteon Declares Quarterly Dividend of $0.375 Per Share Visteon Declares Quarterly Dividend of $0.375 Per Share PR Newswire VAN BUREN TOWNSHIP, Mich., Aug. 17, 2026 VAN BUREN TOWNSHIP, Mich., Aug. 17, 2026 /PRNewswire/ -- Visteon Corporation (NASDAQ: VC), a global leader in automotive cockpit...

Wall Street Analysts Think Visteon (VC) Could Surge 31.08%: Read This Before Placing a Bet

The consensus price target hints at a 31.1% upside potential for Visteon (VC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is Lear (LEA) Stock Outpacing Its Auto-Tires-Trucks Peers This Year?

Here is how Lear (LEA) and Visteon (VC) have performed compared to their sector so far this year.

Visteon (VC) Misses Q2 Earnings Estimates

Visteon (VC) delivered earnings and revenue surprises of -14.35% and +0.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Visteon Corp. Q2 Income Drops

(RTTNews) - Visteon Corp. (VSTOW.OB) released a profit for second quarter that Drops, from the same period last year...

Visteon Announces Second Quarter 2026 Financial Results and $200 Million Accelerated Share Repurchase Program

Visteon Announces Second Quarter 2026 Financial Results and $200 Million Accelerated Share Repurchase Program Visteon Announces Second Quarter 2026 Financial Results and $200 Million Accelerated Share Repurchase Program PR Newswire VAN BUREN TOWNSHIP, Mich., July 23, 2026 VAN BUREN TOWNSHIP, Mich...

Is Visteon (VC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Visteon (VC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Visteon (VC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Visteon Corp. engages in the advancing mobility through innovative technology solutions that enable a software-defined future. The firm’s state-of-the-art product portfolio merges digital cockpit innovations, advanced displays, AI-enhanced software solutions, and integrated EV architecture solutions. The company was founded on January 5, 2000 and is headquartered in Van Buren Township, MI.

Visteon Corp.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$87.25
Prev Close	$88.67
Open	$89.30
Dividend Yield	0.58%
50-Day Moving Average	$96.89
Beta	0.99
Avg. Volume	520,434.28
PE Ratio	15.91

52-Week High	$126.95
52-Week Low	$83.49
Market Capitalization	$2.33B
EPS (Annual)	$7.28
Price to Book	1.45
Revenue Per Employee	$358,857.14

Feed

News

Sentiment

Earnings

Fundamentals

Info

VC Fundamentals